Amicus Therapeutics Inc (NASDAQ:FOLD) has a beta value of 0.76 and has seen 3.7 million shares traded in the last trading session. The company, currently valued at $3.50B, closed the last trade at $11.84 per share which meant it gained $0.26 on the day or 2.25% during that session. The FOLD stock price is -23.06% off its 52-week high price of $14.57 and 18.07% above the 52-week low of $9.70. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.03 million shares traded. The 3-month trading volume is 3.24 million shares.
Amicus Therapeutics Inc (NASDAQ:FOLD) trade information
Sporting 2.25% in the green in last session, the stock has traded in the green over the last five days, when the FOLD stock price touched $11.84 or saw a rise of 0.84%. Year-to-date, Amicus Therapeutics Inc shares have moved -16.56%, while the 5-day performance has seen it change 0.42%. Over the past 30 days, the shares of Amicus Therapeutics Inc (NASDAQ:FOLD) have changed -13.95%. Short interest in the company has seen 30.91 million shares shorted with days to cover at 9.63.
Amicus Therapeutics Inc (FOLD) estimates and forecasts
Figures show that Amicus Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -8.07% over the past 6 months, with this year growth rate of 105.88%, compared to 12.40% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 66.70% and 86.70% for the next quarter. Revenue growth from the last financial year stood is estimated to be 33.00%.
10 analysts offering their estimates for the company have set an average revenue estimate of $111.96 million for the current quarter. 10 have an estimated revenue figure of $125.77 million for the next quarter concluding in Jun 2024. Year-ago sales stood $83.08 million and $94.5 million respectively for this quarter and the next, and analysts expect sales will grow by 34.80% for the current quarter and 33.10% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 22.84% over the past 5 years.
FOLD Dividends
Amicus Therapeutics Inc is expected to release its next earnings report between May 08 and May 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Amicus Therapeutics Inc (NASDAQ:FOLD)’s Major holders
Insiders own 0.76% of the company shares, while shares held by institutions stand at 109.73% with a share float percentage of 110.57%. Investors are also buoyed by the number of investors in a company, with Amicus Therapeutics Inc having a total of 320 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc with over 28.49 million shares worth more than $337.35 million. As of Dec 30, 2023, Vanguard Group Inc held 9.65% of shares outstanding.
The other major institutional holder is Perceptive Advisors Llc, with the holding of over 28.06 million shares as of Dec 30, 2023. The firm’s total holdings are worth over $332.2 million and represent 9.50% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Dec 30, 2023, the former fund manager holds about 3.24% shares in the company for having 9.57 million shares of worth $113.29 million while later fund manager owns 7.51 million shares of worth $88.96 million as of Dec 30, 2023, which makes it owner of about 2.54% of company’s outstanding stock.
